Orion Corp New B Shs (ORINF) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello from sunny Helsinki and welcome to Orion's Q2 2025 earnings conference call and webcast. My name is Tuukka Hirvonen and I'm the head of investor relations here at Orion. In a few moments, our CEO and president, Liisa Hurme, will present the results and key events from the past quarter, followed by the opportunity to ask questions from Liisa and also from our CFO, René Lindell, who is here today also. We will start taking questions first from the conference call lines and then afterwards we will turn to the webcast. So you all have the opportunity to type in your questions using the chat function of the webcast. Kindly state your name and the organization you are representing before asking your question. And also to be noted that recording of this webcast will be available on Orion's website later this afternoon. And also to our Finnish speaking viewers information that also a Finnish interview of the CEO Liisa Hurme will also be available on Orion's website later this afternoon. But without any further delays, I'd like to draw your attention to this familiar disclaimer or safe harbor statement before letting Liisa to take over. Liisa, please. Thank you, Tuukka. And welcome on my behalf as well. I start with saying that all Orion's divisions continued very good performance during the first quarter this year. But before I go to numbers, let's look at some highlights from the second quarter. FDA gave approval and CHMP recommended for approval in EU darolutamide in combination with ADT, androgen deprivation therapy, or the use of darolutamide and ADT in patients with metastatic hormone-sensitive prostate cancer. Our partner MSD has shared information that they have expanded Opevesostat program to women's cancers. And also we shared information in our capital market...